AveXis Announces Single-Arm Design for Pivotal Study of AVXS-101
AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the planned pivotal study of AVXS-101 in spinal muscular atrophy (SMA) Type 1 will reflect a single-arm design, using natural history of the disease as a comparator, and enroll approximately 20 patients. This […]
AveXis Announces Single-Arm Design for Pivotal Study of AVXS-101 Read More »